TrialCurveAMPLITUDE: reconstructed Kaplan–Meier curves
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Med. 2025 Oct 7;31(12):4109–18. doi: 10.1038/s41591-025-03961-8 |
|---|---|
| DOI | 10.1038/s41591-025-03961-8 |
| Registry | NCT04497844 |
| Phase | Phase 3 |
| Conditions | Prostatic Neoplasms |
| Interventions | Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA |
| Sponsor | Janssen Research & Development, LLC |
| Enrolment | 696 |
| Source licence | Figure published under CC BY 4.0 |
Investigator-assessed radiographic progression-free survival — BRCA subgroup (n = 387)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 26.0 months. Survival at 12 months: Niraparib + abiraterone 87%; Abiraterone 76%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.51 (95% CI 0.37–0.71).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 191 | 57 | not reached |
| Abiraterone | 196 | 94 | 26.0 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.51 (95% CI 0.37–0.71)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 96.8% | 92.6% |
| 12 mo | 86.9% | 75.9% |
| 18 mo | 80.2% | 63.9% |
| 24 mo | 73.3% | 56.0% |
| 36 mo | 64.4% | 43.5% |
Checks against the published figure
- Abiraterone median: printed 26, reconstructed 26 pass
- Niraparib + abiraterone events: printed 57, reconstructed 57 pass
- Niraparib + abiraterone n: printed 191, reconstructed 191 pass
- Abiraterone events: printed 93, reconstructed 94 pass
- Abiraterone n: printed 196, reconstructed 196 pass
- hazard ratio (direction inferred): printed 0.52, reconstructed 0.514 pass
Investigator-assessed radiographic progression-free survival — HRR effector subgroup (n = 456)
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 27.4 months. Survival at 12 months: Niraparib + abiraterone 86%; Abiraterone 77%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.58 (95% CI 0.43–0.78).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 230 | 71 | not reached |
| Abiraterone | 226 | 103 | 27.4 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.58 (95% CI 0.43–0.78)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 96.9% | 93.6% |
| 12 mo | 85.9% | 77.0% |
| 18 mo | 78.4% | 66.1% |
| 24 mo | 71.8% | 58.3% |
| 36 mo | 63.1% | 45.4% |
Checks against the published figure
- Abiraterone median: printed 27.6, reconstructed 27.4 pass
- Niraparib + abiraterone events: printed 71, reconstructed 71 pass
- Niraparib + abiraterone n: printed 230, reconstructed 230 pass
- Abiraterone events: printed 102, reconstructed 103 pass
- Abiraterone n: printed 226, reconstructed 226 pass
- hazard ratio (direction inferred): printed 0.57, reconstructed 0.576 pass
Investigator-assessed radiographic progression-free survival — Intention-to-treat population (n = 696)
From figure panel c · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 29.3 months. Survival at 12 months: Niraparib + abiraterone 85%; Abiraterone 77%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.65 (95% CI 0.51–0.83).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 348 | 115 | not reached |
| Abiraterone | 348 | 152 | 29.3 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.65 (95% CI 0.51–0.83)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 97.3% | 93.2% |
| 12 mo | 85.5% | 76.6% |
| 18 mo | 77.3% | 66.7% |
| 24 mo | 70.3% | 59.5% |
| 36 mo | 59.6% | 47.1% |
Checks against the published figure
- Abiraterone median: printed 29.5, reconstructed 29.3 pass
- Niraparib + abiraterone events: printed 113, reconstructed 115 pass
- Niraparib + abiraterone n: printed 348, reconstructed 348 pass
- Abiraterone events: printed 151, reconstructed 152 pass
- Abiraterone n: printed 348, reconstructed 348 pass
- hazard ratio (direction inferred): printed 0.63, reconstructed 0.649 pass
Time to symptomatic progression — BRCA subgroup (n = 387)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 96%; Abiraterone 83%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.45 (95% CI 0.29–0.68).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 191 | 31 | not reached |
| Abiraterone | 196 | 66 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.45 (95% CI 0.29–0.68)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 98.4% | 95.4% |
| 12 mo | 95.7% | 83.4% |
| 18 mo | 91.1% | 75.5% |
| 24 mo | 83.5% | 69.3% |
| 36 mo | 80.4% | 63.5% |
Checks against the published figure
- Niraparib + abiraterone events: printed 31, reconstructed 31 pass
- Niraparib + abiraterone n: printed 191, reconstructed 191 pass
- Abiraterone events: printed 66, reconstructed 66 pass
- Abiraterone n: printed 196, reconstructed 196 pass
- hazard ratio (direction inferred): printed 0.44, reconstructed 0.445 pass
Time to symptomatic progression — Intention-to-treat population (n = 696)
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 96%; Abiraterone 85%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.53 (95% CI 0.38–0.73).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 348 | 58 | not reached |
| Abiraterone | 348 | 104 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.53 (95% CI 0.38–0.73)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 98.8% | 96.5% |
| 12 mo | 96.1% | 85.5% |
| 18 mo | 90.6% | 77.9% |
| 24 mo | 84.9% | 72.4% |
| 36 mo | 78.6% | 67.0% |
Checks against the published figure
- Niraparib + abiraterone events: printed 57, reconstructed 58 pass
- Niraparib + abiraterone n: printed 348, reconstructed 348 pass
- Abiraterone events: printed 104, reconstructed 104 pass
- Abiraterone n: printed 348, reconstructed 348 pass
- hazard ratio (direction inferred): printed 0.5, reconstructed 0.526 pass
Overall survival — BRCA subgroup (n = 387)
From figure panel c · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 95%; Abiraterone 93%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.74 (95% CI 0.50–1.09).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 191 | 44 | not reached |
| Abiraterone | 196 | 61 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.74 (95% CI 0.50–1.09)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 97.9% | 99.0% |
| 12 mo | 94.7% | 92.8% |
| 18 mo | 91.5% | 89.2% |
| 24 mo | 86.3% | 79.7% |
| 36 mo | 70.1% | 61.3% |
Checks against the published figure
- Niraparib + abiraterone events: printed 44, reconstructed 44 pass
- Niraparib + abiraterone n: printed 191, reconstructed 191 pass
- Abiraterone events: printed 61, reconstructed 61 pass
- Abiraterone n: printed 196, reconstructed 196 pass
- hazard ratio (direction inferred): printed 0.75, reconstructed 0.737 pass
Overall survival — Intention-to-treat population (n = 696)
From figure panel d · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 95%; Abiraterone 92%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.79 (95% CI 0.59–1.05).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 348 | 85 | not reached |
| Abiraterone | 348 | 108 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.79 (95% CI 0.59–1.05)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 98.5% | 98.3% |
| 12 mo | 95.3% | 92.5% |
| 18 mo | 88.7% | 87.8% |
| 24 mo | 83.0% | 79.7% |
| 36 mo | 69.8% | 62.1% |
Checks against the published figure
- Niraparib + abiraterone events: printed 85, reconstructed 85 pass
- Niraparib + abiraterone n: printed 348, reconstructed 348 pass
- Abiraterone events: printed 108, reconstructed 108 pass
- Abiraterone n: printed 348, reconstructed 348 pass
- hazard ratio (direction inferred): printed 0.79, reconstructed 0.79 pass
Radiographic progression-free survival (blinded independent central review) — BRCA subgroup (n = 387)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 26.2 months. Survival at 12 months: Niraparib + abiraterone 88%; Abiraterone 71%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.51 (95% CI 0.37–0.72).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 191 | 54 | not reached |
| Abiraterone | 196 | 89 | 26.2 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.51 (95% CI 0.37–0.72)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 97.3% | 92.1% |
| 12 mo | 87.8% | 70.9% |
| 18 mo | 81.3% | 64.5% |
| 24 mo | 72.2% | 52.9% |
| 36 mo | 65.7% | 46.5% |
Checks against the published figure
- Abiraterone median: printed 26.3, reconstructed 26.2 pass
- Niraparib + abiraterone events: printed 54, reconstructed 54 pass
- Niraparib + abiraterone n: printed 191, reconstructed 191 pass
- Abiraterone events: printed 88, reconstructed 89 pass
- Abiraterone n: printed 196, reconstructed 196 pass
- hazard ratio (direction inferred): printed 0.51, reconstructed 0.513 pass
Radiographic progression-free survival (blinded independent central review) — HRR effector subgroup (n = 456)
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 29.5 months. Survival at 12 months: Niraparib + abiraterone 87%; Abiraterone 73%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.58 (95% CI 0.43–0.79).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 230 | 69 | not reached |
| Abiraterone | 226 | 99 | 29.5 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.58 (95% CI 0.43–0.79)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 96.9% | 92.2% |
| 12 mo | 87.2% | 72.9% |
| 18 mo | 80.0% | 66.4% |
| 24 mo | 70.4% | 55.5% |
| 36 mo | 64.9% | 47.9% |
Checks against the published figure
- Abiraterone median: printed 29.5, reconstructed 29.5 pass
- Niraparib + abiraterone events: printed 68, reconstructed 69 pass
- Niraparib + abiraterone n: printed 230, reconstructed 230 pass
- Abiraterone events: printed 97, reconstructed 99 pass
- Abiraterone n: printed 226, reconstructed 226 pass
- hazard ratio (direction inferred): printed 0.58, reconstructed 0.584 pass
Radiographic progression-free survival (blinded independent central review) — Intention-to-treat population (n = 696)
From figure panel c · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone 40.2 months. Survival at 12 months: Niraparib + abiraterone 87%; Abiraterone 75%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.63 (95% CI 0.49–0.82).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 348 | 103 | not reached |
| Abiraterone | 348 | 141 | 40.2 |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.63 (95% CI 0.49–0.82)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 98.2% | 92.6% |
| 12 mo | 87.1% | 75.0% |
| 18 mo | 78.7% | 68.0% |
| 24 mo | 70.9% | 59.2% |
| 36 mo | 65.3% | 50.8% |
Checks against the published figure
- Abiraterone median: printed 40.2, reconstructed 40.2 pass
- Niraparib + abiraterone events: printed 103, reconstructed 103 pass
- Niraparib + abiraterone n: printed 348, reconstructed 348 pass
- Abiraterone events: printed 140, reconstructed 141 pass
- Abiraterone n: printed 348, reconstructed 348 pass
- hazard ratio (direction inferred): printed 0.61, reconstructed 0.634 pass
Time to symptomatic progression — HRR effector subgroup (n = 456)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 96%; Abiraterone 85%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.50 (95% CI 0.33–0.74).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 230 | 37 | not reached |
| Abiraterone | 226 | 69 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.50 (95% CI 0.33–0.74)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 98.7% | 95.6% |
| 12 mo | 95.9% | 84.7% |
| 18 mo | 90.7% | 77.8% |
| 24 mo | 83.7% | 71.9% |
| 36 mo | 81.1% | 66.9% |
Checks against the published figure
- Niraparib + abiraterone events: printed 37, reconstructed 37 pass
- Niraparib + abiraterone n: printed 230, reconstructed 230 pass
- Abiraterone events: printed 69, reconstructed 69 pass
- Abiraterone n: printed 226, reconstructed 226 pass
- hazard ratio (direction inferred): printed 0.49, reconstructed 0.499 pass
Overall survival — HRR effector subgroup (n = 456)
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib + abiraterone not reached; Abiraterone not reached. Survival at 12 months: Niraparib + abiraterone 95%; Abiraterone 93%. Hazard ratio Niraparib + abiraterone vs Abiraterone 0.81 (95% CI 0.57–1.15).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib + abiraterone | 230 | 55 | not reached |
| Abiraterone | 226 | 68 | not reached |
- Niraparib + abiraterone vs Abiraterone: reconstructed HR 0.81 (95% CI 0.57–1.15)
Landmark survival (reconstructed)
| Time | Niraparib + abiraterone | Abiraterone |
|---|---|---|
| 6 mo | 97.8% | 98.7% |
| 12 mo | 95.2% | 92.9% |
| 18 mo | 89.4% | 89.7% |
| 24 mo | 84.2% | 80.2% |
| 36 mo | 70.0% | 62.9% |
Checks against the published figure
- Niraparib + abiraterone events: printed 54, reconstructed 55 pass
- Niraparib + abiraterone n: printed 230, reconstructed 230 pass
- Abiraterone events: printed 67, reconstructed 68 pass
- Abiraterone n: printed 226, reconstructed 226 pass
- hazard ratio (direction inferred): printed 0.81, reconstructed 0.807 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- ESCAPE (metastatic renal cell carcinoma): 1st-line (+ 2nd-line) progression-free survival; 2nd-line progression-free survival; Overa
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials